OQROSign up free
Insider trade

Keros Therapeutics (KROS): Director reported a transaction in 140K shares

ORBIMED ADVISORS LLC, Director at Keros Therapeutics, reported a transaction of 140K shares.

140K
Shares · @ $17.75
Traded
Nov 21, 2025
Filed
Dec 18, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 15, 2025Company filing · Form 8-K · Material agreement, ResultsChanged a top executive or board member, and signed an important agreement (and 3 more items)“In accordance with the terms of the Pontifax Repurchase Agreement, each of Tomer Kariv and Ran Nussbaum have resigned from their respective positions as a member of the Company’s board of directors and all committees thereof, effective as of October 15, 2025.”
  2. Oct 15, 2025Insider · 2 peopleInsiders: 7 sales (~$180.6M)
  3. Nov 5, 2025Company filing · Form 8-K · ResultsReported its results

What came next

  1. Feb 18, 2026Insider · 3 peopleInsiders: 3 sales (~$218K)
  2. Feb 19, 2026InsiderCEO sold ~$113K of KROS shares in the open market
  3. Feb 20, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On February 24, 2026, the board of directors (the “Board”) of Keros Therapeutics, Inc. (the “Company”), based upon a recommendation from the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), voted to appoint Charles Newton as a director of the Company, effective on March 9, 2026.”
  4. Mar 4, 2026Company filing · Form 8-K · ResultsReported its results
  5. Mar 9, 2026Insider · Their first buy on recordDirector purchased ~$22K of KROS shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Keros Therapeutics

For Keros Therapeutics, OQRO holds 6 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its KROS page.

Other recent filings by ORBIMED ADVISORS LLC, Director

The full history of ORBIMED ADVISORS LLC, Director is on the profile page.

How this filing works

Explore the data

Other disclosures at Keros Therapeutics

Everything OQRO holds on this company is on its KROS page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Sign up freeAlready have an account? Log in

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data